ArticleAnnals of hematology2026

SF3B1 mutation as a predictive biomarker for luspatercept efficacy in myeloproliferative neoplasms and MDS/MPN: a clinical study.

Tingting Cui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.